|
|
|
| |
| Company Profile |
| |
|
CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer and infectious diseases. The company owns a pre-clinical technology called ligand epitope antigen presentation system (L.E.A.P.S) that designs and synthesizes proprietary peptide immunogens. Its products include Multikine, an immunotherapeutic agent that is used for the treatment of cancer and CEL-1000 peptide, a product developed through its L.E.A.P.S, which provides protection in animals against malaria, herpes, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was formed in 1983 and is headquartered in Vienna, Virginia.
|
CEL SCI CP Related |
|
CVM: Summary for CEL SCI CP - Yahoo! Finance Get detailed information on CEL SCI CP (CVM) including quote performance, Real ... CEL-SCI Takes Delivery of New Manufacturing Facility PR Newswire(Thu, Oct 9) ...
|
|
CVM: Headlines for CEL SCI CP - Yahoo! Finance Find out the latest news headlines for CEL SCI CP (CVM) ... New Data Points to Long Lasting Beneficial Effects of CEL-SCI's Rheumatoid Arthritis Vaccine ...
|
|
CVM CEL-SCI CP Analysis of CVM, CEL-SCI CP in American and Canadian Stock Markets NYSE, NASDAQ, AMEX, OTC, TSX,and CDNX, End-of-Day Stock Data, Alert Signals Buy, Sell, Hold; ...
|
|
